{
  "abstract": "Dopamine D2 receptor (DRD2) agonists represent a promising targeted, nonhormonal therapeutic strategy for endometriosis. These agents selectively downregulate vascular endothelial growth factor-A signaling, thereby inhibiting the aberrant angiogenesis that supports the survival and proliferation of endometriotic lesions. This review synthesizes preclinical and early clinical evidence on DRD2 targeting, with a focus on the clinical translation of cabergoline and quinagolide. In a randomized, double-blind, placebo-controlled pilot trial, a 6-month cabergoline regimen significantly reduced chronic pelvic pain scores and improved pain relief without serious adverse events. Additionally, post hoc analysis of lesion regression showed that 61.3% of lesions in the quinagolide group demonstrated regression, while ovulatory function was preserved in 93% of participants, consistent with maintenance of the hypothalamic-pituitary-ovarian axis. Collectively, these data suggest that DRD2 agonists may represent a fertility-compatible, mechanistically targeted therapeutic approach and underscore the need for adequately powered phase 3 clinical trials.",
  "abstract_shown": true,
  "affiliations": [
    "Ohio State University, Columbus, Ohio.",
    "Endometriosis Society India, Kolkata, India."
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Rahi Tinni Basu"
    },
    {
      "affs": [
        1
      ],
      "name": "Pradip Kumar Mitra"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/f0a6szp613ce1.bib",
  "cited_by": 0,
  "doi": "10.1016/j.xfre.2026.07.005",
  "fulltext_url": "https://europepmc.org/articles/PMC13681272",
  "id": "f0a6szp613ce1",
  "issns": [
    "2666-3341"
  ],
  "landing_url": "https://europepmc.org/article/MED/42903633",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2743|Endometriosis Research and Treatment"
    ]
  ],
  "openalex": "W7170061276",
  "pdf_url": "https://europepmc.org/articles/PMC13681272?pdf=render",
  "pmcid": "PMC13681272",
  "pmid": "42903633",
  "published": "2026-07-22",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/f0a6szp613ce1.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:59Z",
      "native_id": "MED:42903633",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42903633"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2743|Endometriosis Research and Treatment",
      "subfield": "reproductive-child"
    }
  ],
  "title": "Nonhormonal management of endometriosis: Role of dopamine D2 receptor agonists in preserving fertility and ovarian function.",
  "title_text": "Nonhormonal management of endometriosis: Role of dopamine D2 receptor agonists in preserving fertility and ovarian function.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:59Z",
  "url": "https://research.draconitic.com/paper/f0a6szp613ce1",
  "venue": "F&S reports",
  "versions": []
}